Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Tocilizumab

Brand: RoActemra┬«
NICE TA: 
Indication: LMMG RA Biologic Pathway (Subcutaneous at all levels where IV is used)
Disease category: Musculoskeletal and joint diseases
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Subcutaneous Tocilizumab is recommended for use as an alternative to intravenous Tocilizumab providing the patient meets the prescribing criteria as set out in NICE technology appraisals for 1st, 2nd and 3rd line use to treat active rheumatoid arthritis (RA) and the agreed Lancashire Rheumatology Alliance flexes for use as monotherapy.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red